Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Receivables for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 38.65% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 38.65% year-over-year, with the annual reading at $2.0 million for FY2025, 38.65% up from the prior year.
  • Receivables for Q4 2025 was $2.0 million at Caribou Biosciences, down from $2.1 million in the prior quarter.
  • The five-year high for Receivables was $6.6 million in Q4 2021, with the low at $832000.0 in Q2 2021.
  • Average Receivables over 5 years is $2.8 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Receivables surged 348.99% in 2021, then plummeted 66.09% in 2025.
  • Over 5 years, Receivables stood at $6.6 million in 2021, then plummeted by 63.58% to $2.4 million in 2022, then grew by 0.7% to $2.4 million in 2023, then plummeted by 41.54% to $1.4 million in 2024, then skyrocketed by 38.65% to $2.0 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $2.0 million, $2.1 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.